Optimizing Patient Outcomes in Metastatic Triple-Negative Breast Cancer

Overview of Metastatic TNBC

Case 1: Introduction

OlympiAD: Olaparib in Patients With mBC and Germline BRCA Mutations

EMBRACA: Talazoparib in Patients With mBC and Germline BRCA Mutations

Using PARP Inhibitors in BRCA-Mutated MBC

Case 2: Introduction

First-Line Treatment of mTNBC IMpassion130: Nab-Paclitaxel + Atezolizumab

Testing for PD-L1 in Patients With TNBC

Considerations With Checkpoint Inhibitors

Treatment of PD-L1-Negative, Germline BRCA-WT mTNBC

What About Chemotherapy Doublets? Expert Perspectives

What If Patients Are PD-L1-Positive and Germline BRCA Mutation-Positive?

Second- and Third-Line Treatment of mTNBC

Making Treatment Decisions in mTNBC

Considering Clinical Trials in mTNBC

Future Directions in mTNBC: Antibody-Drug Conjugates

Future Directions in mTNBC: Other Approaches

Shared Decision-Making Principles

Direct Patients to Reputable Resources

Key Takeaways

Abbreviations

Abbreviations (cont)